ROME THERAPEUTICS
ROME Therapeutics is developing novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome – vast stretches of uncharted genetic material that have long been dismissed as “junk DNA.” With several drug targets identified and multiple discovery programs underway, ROME is moving rapidly to leverage this new frontier in biology. To lead this exploration, ROME has assembled a team of world-class leaders across fields including oncology, immunology, virology and machine learning.
ROME THERAPEUTICS
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2020-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.rometx.com
Total Employee:
11+
Status:
Active
Total Funding:
127 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Google Tag Manager WordPress Google Universal Analytics
Similar Organizations
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Arvinas
Arvinas advances therapies degrading disease-causing proteins for life-threatening diseases, from discovery to commercialization.
Dracen Pharmaceuticals
Dracen Pharmaceuticals is a developer of novel glutamine antagonists created to deliver improved outcomes for cancer patients.
Dyne Therapeutics
Dyne Therapeutics is a developer of targeted therapies intended for serious muscle diseases.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Genomic Prediction
Genomic Prediction provides advanced genetic testing for IVF.
Obsidian Therapeutics
Obsidian Therapeutics is a developer of a next-generation cell and gene therapies created to extend adoptive immunotherapy.
Regenosine, Inc
Regenosine is developing a first-in-class disease-modifying regenerative therapy for osteoarthritis.
Royal Emerald Pharmaceuticals
Royal Emerald Pharmaceuticals produces non-addictive alternate medicines for dilemmas of PTSD and other health consequences.
Tiburio Therapeutics
Tiburio Therapeutics is a developer of drug compounds intended to treat tumors and endocrine diseases.
VasoRx
VasoRx is developing RNA therapies for diseases of the cardiovascular system & oncology such as atherosclerosis and pulmonary hypertension.
Zucara Therapeutics
Zucara Therapeutics is developing the first once-daily therapeutic to prevent hypoglycemia (low blood sugar) in patients with diabetes.
Current Advisors List
Current Employees Featured
Founder
Investors List
Section 32
Section 32 investment in Series B - ROME Therapeutics
Mass General Brigham Ventures
Mass General Brigham Ventures investment in Series B - ROME Therapeutics
Andreessen Horowitz
Andreessen Horowitz investment in Series B - ROME Therapeutics
Casdin Capital
Casdin Capital investment in Series B - ROME Therapeutics
ARCH Venture Partners
ARCH Venture Partners investment in Series B - ROME Therapeutics
GV
GV investment in Series B - ROME Therapeutics
Alexandria Venture Investments
Alexandria Venture Investments investment in Series B - ROME Therapeutics
Sanofi Ventures
Sanofi Ventures investment in Series B - ROME Therapeutics
ARCH Venture Partners
ARCH Venture Partners investment in Series A - ROME Therapeutics
GV
GV investment in Series A - ROME Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2022-04-26 | ROME Therapeutics Appoints Nurjana Bachman, Ph.D., as Senior Vice President, Corporate Development and Strategy |
Official Site Inspections
http://www.rometx.com Semrush global rank: 3.29 M Semrush visits lastest month: 4.97 K
- Host name: 149.51.237.35.bc.googleusercontent.com
- IP address: 35.237.51.149
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
More informations about "ROME Therapeutics"
Home – ROME Therapeutics - rometx.com
Nov 21, 2024 · At ROME Therapeutics, we are illuminating the dark genome to pioneer a new approach to treating serious diseases. For decades, drug discovery has focused on just 2% of …See details»
About Us – ROME Therapeutics - rometx.com
Our world-class scientific team brings together leading experts in oncology, immunology, machine learning, virology and even theoretical physics. We have partnerships with top academic labs …See details»
News – ROME Therapeutics - rometx.com
Apr 2, 2024 · ROME Therapeutics to Present Data Supporting LINE-1 Reverse Transcriptase Inhibitors as a Novel Treatment for Autoimmune Diseases at ACR Convergence 2024. ROME …See details»
ROME Therapeutics - Crunchbase Company Profile
ROME Therapeutics is developing novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome. ROME Therapeutics may be growing as it has successfully secured a significant investment to boost its …See details»
ROME Therapeutics - Overview, News & Similar companies
View ROME Therapeutics (www.rometx.com) location in Massachusetts, United States , revenue, industry and description. Find related and similar companies as well as employees by title and …See details»
Rome Therapeutics, Inc. Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Rome Therapeutics, Inc. of Boston, MA. Get the latest business insights from Dun & Bradstreet.See details»
ROME Therapeutics | LinkedIn
ROME Therapeutics is developing novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome – vast stretches of uncharted genetic material that …See details»
ROME Therapeutics Appoints Keith Wilcoxen, Ph.D., as Executive …
Mar 9, 2023 · ROME Therapeutics today announced the appointment of Keith Wilcoxen, Ph.D., as Executive Vice President, Early Development.See details»
Rome Therapeutics - VentureRadar
Website: https://rometx.com/ Develops novel therapies for serious diseases such as cancer and autoimmune disease by exploring the role of the dark genome. VentureRadar Research / …See details»
ROME Therapeutics Debuts First Preclinical Data of its LINE-1 …
Nov 21, 2024 · ROME’s lead program, a LINE-1 RT inhibitor for Type 1 interferonopathies, has the potential to be the first non-immunosuppressant treatment for autoimmune diseases. …See details»
ROME Therapeutics Announces Publication of First Crystal …
Jun 30, 2022 · ROME Therapeutics is developing novel therapies for cancer and autoimmune diseases by harnessing the power of the dark genome, vast stretches of uncharted genetic …See details»
ROME Therapeutics Information - RocketReach
ROME Therapeutics is a Biotechnology Research, Drug Discovery, and Biotechnology company located in Boston, Massachusetts with 50 employees. Find top employees, contact details and …See details»
Working at Rome – ROME Therapeutics - rometx.com
At ROME, our dedication to innovation shows up in everything we do, from the lab bench to our company culture. We Romans love the joy of pioneering a new frontier in biology and the …See details»
Rome Therapeutics - Craft
See insights on Rome Therapeutics including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»
ROME Therapeutics Appoints Scientist and Entrepreneur
Mar 1, 2021 · ROME Therapeutics is developing novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome – vast stretches of uncharted genetic …See details»
Rome Therapeutics, Inc. | Insights
Sep 19, 2023 · Already A Biomedtracker Subscriber? You have access to the full company record through your subscription.See details»
ROME Publishes Landmark - Business Wire
Dec 14, 2023 · ROME Therapeutics today announced a landmark publication in Nature revealing the first high-resolution structure of the LINE-1 reverse transcriptase.See details»
ROME Therapeutics Secures $77 Million in Series B Financing to …
CAMBRIDGE, Mass. – September 14, 2021 – ROME Therapeutics, a biotechnology company harnessing the power of the repeatome for drug development, today announced the …See details»
人体“垃圾DNA”究竟有何妙用？ROME Therapeutics获5000万美元A …
Apr 28, 2020 · 根据外媒报道，专注于利用靶向重复基因组（repeatome）的技术开发药物的ROME Therapeutics（以下简称：ROME ）已完成5000万美元A轮融资，以开发靶向“垃圾DNA”的新 …See details»
ROME Publishes Landmark - rometx.com
BOSTON – December 14, 2023 – ROME Therapeutics, a biotechnology company harnessing the power of the dark genome to develop breakthrough medicines for serious diseases, today …See details»